Supplementary Files
Keywords
Antiplatelet agents
Aspirin
Preeclampsia
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To discuss preeclampsia in pregnant women and the use of antiplatelet agents to prevent this disease in an updated way. Bibliographic review: Preeclampsia is a pregnancy-related condition that can be fatal for both mother and fetus. It is one of the main causes of maternal morbidity and mortality in Brazil. It is characterized by high blood pressure, significant edema, and proteinuria. The use of ASA, an antiplatelet agent, in patients at high risk or who had previously had preeclampsia was shown to be beneficial and safe in preventing the disease in the studies evaluated. Final considerations: The use of ASA at low doses in patients at risk of developing preeclampsia shows good evidence, however, there is still no global consensus on doses, when to start treatment or how to properly screen pregnant women. There is still a need to find new therapies for the disease and improve maternal and fetal outcomes in patients who developed PE even after using ASA.
References
ATALLAH A, et al. Aspirin for Prevention of Preeclampsia. Drugs, 2017; 77(17): 1819–1831.
BASCHAT AA, et al. Maternal blood-pressure trends throughout pregnancy and development of pre-eclampsia in women receiving first-trimester aspirin prophylaxis. Ultrasound Obstet Gynecol, 2018; 52(6): 728-733.
BRAGA JC, et al. Gravidez na adolescência como fator de risco para pré-eclâmpsia. Revisão sistemática da literatura. Revista Multidisciplinar da Saúde, 2021; 3(2): 37-49.
DULEY L, et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Ver, 2019; (10): CD004659.
DULEY L. Antiagregantes plaquetários para prevenção da pré‐eclâmpsia e suas complicações: uma Revisão Cochrane. JBMEDE-Jornal Brasileiro de Medicina de Emergência, 2021;1(2): e21016-e21016.
EVERETT TR, et al. Pre-eclampsia: the Potential of GSNO Reductase Inhibitors. Curr Hypertens Rep, 2017;19(3): 20.
GOMES TB, et al. Pré-eclâmpsia: importante causa de óbitos maternos no Brasil entre os anos de 2010-2017. Braz. J. of Develop, 2020; 6(10): 75496-75510
HAMULYÁK EN, et al. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database Syst Ver, 2020; 5(5): CD012852.
HOFFMAN MK, et al. Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. Lancet. 2020; 395(10220): 285-293.
HUAI J, et al. Preventive effect of aspirin on preeclampsia in high-risk pregnant women with stage 1 hypertension. Journal of clinical hypertension (Greenwich, Conn.), 2021; 23(5): 1060–1067.
KAHHALE S, et al. Pré-eclâmpsia. Revista de Medicina, 2018; 97(2): 226-234.
LIN L, et al. APPEC Study Group. Low-dose aspirin in the prevention of pre-eclampsia in China (APPEC study): protocol for a multicentre randomized controlled trial. Trials, 2018; 19(1): 608.
MA'AYEH M, et al. Novel Interventions for the Prevention of Preeclampsia. Current hypertension reports, 2020; 22(2): 17.
MACHADO NC. Pré-eclâmpsia na gravidez sob a ótica das mulheres da região noroeste do Estado do Rio Grande do Sul, Brasil. O Mundo da Saúde, 2020; 1(44): 498-505.
MAI CM, et al. Assistência de enfermagem em mulheres com pré-eclâmpsia e/ou eclâmpsia: uma revisão integrativa da literatura. Boletim de Conjuntura (BOCA), 2021; 8(23): 28-39.
MIRABITO COLAFELLA KM, et al. Aspirin for the prevention and treatment of pre-eclampsia: A matter of COX-1 and/or COX-2 inhibition? Basic Clin Pharmacol Toxicol, 2020; 127(2): 132-141.
RAY A, RAY S. Epidural therapy for the treatment of severe pre-eclampsia in non labouring women. Cochrane Database Syst Ver, 2017; 11(11): CD009540.
REIS-DE-CARVALHO C. Análise da Revisão Cochrane: O Papel dos Antiagregantes Plaquetários para Prevenir a Pré-Eclâmpsia e as Suas Complicações. Acta Medica Portuguesa, 2021; 34: 12.
ROBERGE S, et al. Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage. Am J Obstet Gynecol, 2018; 218(5): 483-489
ROLNIK D, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med, 2017; 377(7): 613-622.
SERRANO CV. Posicionamento sobre antiagregantes plaquetários e anticoagulantes em cardiologia-2019. Arquivos Brasileiros de Cardiologia, 2019; 113: 111-134.
TOLCHER MC, et al. Low-dose aspirin for preeclampsia prevention: efficacy by ethnicity and race. Am J Obstet Gynecol MFM, 2020; 2(4): 100184.
YANG S, et al. Ameliorative effects of pre-eclampsia by quercetin supplement to aspirin in a rat model induced by L-NAME. Biomed Pharmacother, 2019;116: 108969.